A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(10 sites)

United States

California Clinical Trials Medical Group (CCTMG), Glendale, California

Children's Hospital Los Angeles, Los Angeles, California

Rush University Medical Center, Chicago, Illinois

LA Center for Bleeding and Clotting Disorders - Metairie, Metairie, Louisiana

University of Michigan Hospitals - Michigan Medicine, Ann Arbor, Michigan

Washington University School of Medicine, St Louis, Missouri

Brody School of Medicine at East Carolina University, Greenville, North Carolina

Penn State Milton S Hershey Medical Center Pediatrics, Hershey, Pennsylvania

Perelman Center for Advanced Medicine (PCAM)- Penn Blood Disorders Program, Philadelphia, Pennsylvania

Canada

McMaster University Medical Centre, Hamilton Health Sciences, Hamilton, Ontario